Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors' reply

Authors :: Sara, Rundquist
Michael C, Sachs
Carl, Eriksson
Ola, Olén
Scott, Montgomery
Jonas, Halfvarson
Source :: Alimentary pharmacologytherapeuticsREFERENCES. 53(9)
Publication Year :: 2021

Subjects :: Sweden
Biological Products
Pharmaceutical Preparations
Tumor Necrosis Factor-alpha
Humans
Antibodies, Monoclonal, Humanized
Inflammatory Bowel Diseases

Tools